Benzinga | Nov 23, 2021 04:31PM EST

Outlook Therapeutics Announces $10M Bought Deal Offering Of Common Stock

Outlook Therapeutics, Inc. (NASDAQ:OTLK) ("Outlook Therapeutics"), alate clinical-stagebiopharmaceutical companyworking to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 8,000,000 shares of common stock of Outlook Therapeutics, at a price to the public of $1.25 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about November 29, 2021, subject to satisfaction of customary closing conditions.